Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

Journal of Clinical Oncology, Vol 24, No 34 (December 1), 2006: pp. 5350-5357
© 2006 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2006.06.4766

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Álvaro, T.
Right arrow Articles by Pons, L. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Álvaro, T.
Right arrow Articles by Pons, L. E.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Immunohistochemical Patterns of Reactive Microenvironment Are Associated With Clinicobiologic Behavior in Follicular Lymphoma Patients

Tomás Álvaro, Marylène Lejeune, Maria-Teresa Salvadó, Carlos Lopez, Joaquín Jaén, Ramón Bosch, Lluis E. Pons

From the Department of Pathology, Hospital Verge de la Cinta, Tortosa, Spain

Address reprint requests to Tomás Álvaro-Naranjo, MD, PhD, Department of Pathology, Hospital de Tortosa Verge de la Cinta, C/Esplanetes No. 14, 43500 Tortosa, Spain; e-mail: talvaro.htvc.ics{at}gencat.net

PURPOSE: Recent molecular data have suggested that non-neoplastic cells are powerful modulators that may confer a selective advantage or disadvantage on the outcome of follicular lymphoma (FL) patients.

PATIENTS AND METHODS: The prevalence of the principal inflammatory and immune-infiltrated cells was measured immunohistochemically in the tissue of 211 FL patients, and associations were sought with their traditional clinicobiologic characteristics.

RESULTS: Our results confirmed the presence of a large number of T lymphocytes (CD4+ and CD8+) and CD57+ cells and, at a moderate level, the presence of TIA-1+ cytotoxic cells, CD68+ macrophages, CD123+ plasmacytoid cells, and FOXP3+ regulatory T cells among the pool of non-neoplastic cells. In addition to the conventional clinical variables, univariate analysis identified a low level of infiltrated CD8+ T lymphocytes as a significantly negative prognostic factor of overall survival. The following significant differences in the abundance of cells of specific and nonspecific immunity were observed in relation to the clinicobiologic features of FL: (1) a reactive microenvironment mainly made up of T lymphocytes and macrophages was significantly associated with a favorable clinical behavior of FL patients; and (2) a reactive microenvironment infiltrated predominantly by CD57+ T cells was associated with a significantly higher frequency of adverse clinicobiologic manifestations such as "B" symptoms and bone marrow involvement.

CONCLUSION: Our results demonstrate the existence of two specific patterns in the reactive microenvironment of FL, an immunosurveillance pattern (T lymphocytes and macrophages) and an immune-escape pattern (CD57+ T cells), that were directly associated with the clinicobiologic features of these patients.

Supported by Grants No. G03/179 and FIS 05/0474 from the Ministerio de Ciencia y Tecnología, Spain.

Some results were presented at XXII Jornades Mèdiques i Ciències de la Salut de les Terres de L’Ebre, February 24–25, 2006, Tortosa, Spain.

Authors’ disclosures of potential conflicts of interest and author contributions are found at the end of this article.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
Ann OncolHome page
J. W. Sweetenham, B. Goldman, M. L. LeBlanc, J. R. Cook, R. R. Tubbs, O. W. Press, D. G. Maloney, R. I. Fisher, L. M. Rimsza, R. M. Braziel, et al.
Prognostic value of regulatory T cells, lymphoma-associated macrophages, and MUM-1 expression in follicular lymphoma treated before and after the introduction of monoclonal antibody therapy: a Southwest Oncology Group Study
Ann. Onc., October 29, 2009; (2009) mdp460v1.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
J. A. Burger, P. Ghia, A. Rosenwald, and F. Caligaris-Cappio
The microenvironment in mature B-cell malignancies: a target for new treatment strategies
Blood, October 15, 2009; 114(16): 3367 - 3375.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
A. Andersson, S.-C. Yang, M. Huang, L. Zhu, U. K. Kar, R. K. Batra, D. Elashoff, R. M. Strieter, S. M. Dubinett, and S. Sharma
IL-7 Promotes CXCR3 Ligand-Dependent T Cell Antitumor Reactivity in Lung Cancer
J. Immunol., June 1, 2009; 182(11): 6951 - 6958.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
H. Maby-El Hajjami, P. Ame-Thomas, C. Pangault, O. Tribut, J. DeVos, R. Jean, N. Bescher, C. Monvoisin, J. Dulong, T. Lamy, et al.
Functional Alteration of the Lymphoma Stromal Cell Niche by the Cytokine Context: Role of Indoleamine-2,3 Dioxygenase
Cancer Res., April 1, 2009; 69(7): 3228 - 3237.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
J. Carreras, A. Lopez-Guillermo, G. Roncador, N. Villamor, L. Colomo, A. Martinez, R. Hamoudi, W. J. Howat, E. Montserrat, and E. Campo
High Numbers of Tumor-Infiltrating Programmed Cell Death 1-Positive Regulatory Lymphocytes Are Associated With Improved Overall Survival in Follicular Lymphoma
J. Clin. Oncol., March 20, 2009; 27(9): 1470 - 1476.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
P. Salama, M. Phillips, F. Grieu, M. Morris, N. Zeps, D. Joseph, C. Platell, and B. Iacopetta
Tumor-Infiltrating FOXP3+ T Regulatory Cells Show Strong Prognostic Significance in Colorectal Cancer
J. Clin. Oncol., January 10, 2009; 27(2): 186 - 192.
[Abstract] [Full Text] [PDF]


Home page
haematolHome page
M. Lejeune and T. Alvaro
Clinicobiological, prognostic and therapeutic implications of the tumor microenvironment in follicular lymphoma
Haematologica, January 1, 2009; 94(1): 16 - 21.
[Full Text] [PDF]


Home page
haematolHome page
D. de Jong, A. Koster, A. Hagenbeek, J. Raemaekers, D. Veldhuizen, S. Heisterkamp, J. P. de Boer, and M. van Glabbeke
Impact of the tumor microenvironment on prognosis in follicular lymphoma is dependent on specific treatment protocols
Haematologica, January 1, 2009; 94(1): 70 - 77.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Med. Inform. Assoc.Home page
C. Lopez, M. Lejeune, P. Escriva, R. Bosch, M. T. Salvado, L. E. Pons, J. Baucells, X. Cugat, T. Alvaro, and J. Jaen
Effects of Image Compression on Automatic Count of Immunohistochemically Stained Nuclei in Digital Images
J. Am. Med. Inform. Assoc., November 1, 2008; 15(6): 794 - 798.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
K. R. Calvo, B. Dabir, A. Kovach, C. Devor, R. Bandle, A. Bond, J. H. Shih, and E. S. Jaffe
IL-4 protein expression and basal activation of Erk in vivo in follicular lymphoma
Blood, November 1, 2008; 112(9): 3818 - 3826.
[Abstract] [Full Text] [PDF]


Home page
CA Cancer J ClinHome page
M. Bendandi
Aiming at a Curative Strategy for Follicular Lymphoma
CA Cancer J Clin, September 1, 2008; 58(5): 305 - 317.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
M. Travert, P. Ame-Thomas, C. Pangault, A. Morizot, O. Micheau, G. Semana, T. Lamy, T. Fest, K. Tarte, and T. Guillaudeux
CD40 Ligand Protects from TRAIL-Induced Apoptosis in Follicular Lymphomas through NF-{kappa}B Activation and Up-Regulation of c-FLIP and Bcl-xL
J. Immunol., July 15, 2008; 181(2): 1001 - 1011.
[Abstract] [Full Text] [PDF]


Home page
haematolHome page
P. P. Piccaluga, A. Califano, U. Klein, C. Agostinelli, B. Bellosillo, E. Gimeno, S. Serrano, F. Sole, Y. Zang, B. Falini, et al.
Gene expression analysis provides a potential rationale for revising the histological grading of follicular lymphomas
Haematologica, July 1, 2008; 93(7): 1033 - 1038.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
M. Taskinen, M.-L. Karjalainen-Lindsberg, and S. Leppa
Prognostic influence of tumor-infiltrating mast cells in patients with follicular lymphoma treated with rituximab and CHOP
Blood, May 1, 2008; 111(9): 4664 - 4667.
[Abstract] [Full Text] [PDF]


Home page
haematolHome page
A. Tzankov, C. Meier, P. Hirschmann, P. Went, S. A. Pileri, and S. Dirnhofer
Correlation of high numbers of intratumoral FOXP3+ regulatory T cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin's lymphoma
Haematologica, February 1, 2008; 93(2): 193 - 200.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
D. Canioni, G. Salles, N. Mounier, N. Brousse, M. Keuppens, F. Morchhauser, T. Lamy, A. Sonet, M.-C. Rousselet, C. Foussard, et al.
High Numbers of Tumor-Associated Macrophages Have an Adverse Prognostic Value That Can Be Circumvented by Rituximab in Patients With Follicular Lymphoma Enrolled Onto the GELA-GOELAMS FL-2000 Trial
J. Clin. Oncol., January 20, 2008; 26(3): 440 - 446.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
M. Taskinen, M.-L. Karjalainen-Lindsberg, H. Nyman, L.-M. Eerola, and S. Leppa
A High Tumor-Associated Macrophage Content Predicts Favorable Outcome in Follicular Lymphoma Patients Treated with Rituximab and Cyclophosphamide-Doxorubicin-Vincristine-Prednisone
Clin. Cancer Res., October 1, 2007; 13(19): 5784 - 5789.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
W. Klapper, E. Hoster, L. Rolver, C. Schrader, D. Janssen, M. Tiemann, H.-W. Bernd, O. Determann, M.-L. Hansmann, P. Moller, et al.
Tumor Sclerosis but Not Cell Proliferation or Malignancy Grade Is a Prognostic Marker in Advanced-Stage Follicular Lymphoma: The German Low Grade Lymphoma Study Group
J. Clin. Oncol., August 1, 2007; 25(22): 3330 - 3336.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
D. Focosi and M. Petrini
CD57 Expression on Lymphoma Microenvironment As a New Prognostic Marker Related to Immune Dysfunction
J. Clin. Oncol., April 1, 2007; 25(10): 1289 - 1291.
[Full Text] [PDF]


Home page
JCOHome page
T. Alvaro, M. Lejeune, M.-T. Salvado, C. Lopez, P. Escriva, J. Jaen, R. Bosch, and L. E. Pons
In Reply
J. Clin. Oncol., April 1, 2007; 25(10): 1291 - 1292.
[Full Text] [PDF]


Home page
ASH Education BookHome page
Y. Natkunam
The Biology of the Germinal Center
Hematology, January 1, 2007; 2007(1): 210 - 215.
[Abstract] [Full Text] [PDF]


Home page
ASH Education BookHome page
G. A. Salles
Clinical Features, Prognosis and Treatment of Follicular Lymphoma
Hematology, January 1, 2007; 2007(1): 216 - 225.
[Abstract] [Full Text] [PDF]



About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 PDA Services

Copyright © 2006 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online